Frequency of radiographic progression by level of clinical response.
| Percentage of Progressors | |||
|---|---|---|---|
| Adalimumab plus MTX | Adalimumab | MTX | |
| By Week-26 ACR response | |||
| < ACR20 | 37* | 49 | 59 |
| ACR20 | 24*** | 40** | 55 |
| ACR50 | 23*** | 37* | 51 |
| ACR70 | 23*** | 33† | 49 |
| By Week-104 ACR response | |||
| < ACR20 | 38* | 53 | 75 |
| ACR20 | 33*** | 53 | 62 |
| ACR50 | 31*** | 53 | 60 |
| ACR70 | 28*** | 53 | 57 |
| By Week-104 remission-like response | |||
| TJC = 0 | 32** | 47 | 59 |
| DAS28 > 2.6 | 33** | 39 | 53 |
| SJC = 0 | 34 | 37 | 44 |
| ACR100 | 32 | 0 | 46 |
Radiographic progression = ΔTSS > 0.5 from baseline. Percentages of progressors are for the same timepoints as indicated for the clinical response categories.
↵* p < 0.05,
↵** p < 0.01,
↵*** p < 0.001,
↵† p = 0.07 vs MTX monotherapy. For comparisons of adalimumab plus MTX vs adalimumab monotherapy, for < ACR20, ACR20, ACR50, ACR70 groups: p = NS, p = 0.001, p < 0.05, p = NS at Week 26 and p = NS, p < 0.001, p < 0.001, p < 0.001 at Week 104. For remission-like response groups, p values are all NS. Patient numbers (n) in clinical outcome subgroups are indicated in Figures 2A, 2B, and 5. ACR: American College of Rheumatology, DAS28: 28-joint Disease Activity Score, MTX: methotrexate, SJC: swollen joint count, TJC: tender joint count, TSS: total Sharp score; NS: not significant.